Tampere University Hospital Launches Beta Cell Preservation Trials
Tampere University Hospital (TAYS) has launched two new clinical trials aimed at slowing the progression of type 1 diabetes and preserving the body’s natural insulin production. Researchers are currently recruiting participants aged 2 to 36 for these trials, which address a condition associated with an average life expectancy reduction of approximately 15 years.
Targeting Pancreatic Function in New Patients
Type 1 diabetes is an autoimmune condition where the pancreas stops producing insulin due to the destruction of beta cells. The research conducted at TAYS focuses on maintaining the function of these remaining beta cells for as long as possible.
Drug Repurposing: From Arthritis to Diabetes
One of the trials utilizes baricitinib, a tablet originally developed to treat other autoimmune conditions such as rheumatoid arthritis and alopecia areata. By repurposing this medication, researchers hope to stabilize insulin levels and simplify long-term disease management. A second study is currently investigating a drug known as frexalimab.
Technological Integration in Pediatric Care
While type 1 diabetes continues to present serious health risks, patient outcomes have improved significantly. Pediatric endocrinologist Salla Kuusela of TAYS notes that the integration of continuous glucose monitoring and “smart” insulin pumps has transformed daily care. These devices regulate insulin based on sensor data, reducing the burden on patients to manually adjust for every fluctuation.
The research environment at TAYS is designed to be accessible; as a pediatric endocrinologist, Kuusela is able to coordinate the requirements of these clinical trials with standard outpatient clinic visits, minimizing the travel and time commitment for families.
Global Regulatory Shifts and Patient Eligibility
The search for disease-modifying therapies is a global priority. In the United States and Europe, regulators have already approved teplizumab, a biological drug designed to delay the onset of clinical type 1 diabetes in high-risk individuals. The Finnish Medicines Agency (Fimea) is currently evaluating whether to implement similar treatments for patients in Finland.
When recruiting for these studies, researchers emphasize that gender does not influence eligibility. However, medical teams do account for biological factors such as puberty, physical growth, and hormonal shifts, as these elements are known to influence both the development of the disease and individual insulin requirements for all patients.
Related reading